Podsumowanie
Depresja u kobiet w wieku rozrodczym, w tym depresja w okresie ciąży i poporodowa, jest poważnym problemem zdrowotnym, który wymaga uwagi oraz odpowiedniego leczenia. Najważniejsze znaczenie mają: wczesne rozpoznanie zaburzeń depresyjnych, uwzględnienie planów rozrodczych pacjentki oraz dostosowanie leczenia do jej indywidualnych potrzeb. Odpowiednia opieka i wsparcie mogą znacząco poprawić jakość życia kobiety oraz jej rodziny, a także zapewnić zdrowy rozwój dziecka. Interdyscyplinarna współpraca specjalistów, w tym ginekologów, psychiatrów i psychoterapeutów, jest kluczowa w zapewnieniu kompleksowej opieki pacjentkom z zaburzeniami depresyjnymi w okresie okołoporodowym.
ABSTRACT
Young women with depression planning to conceive: collaboration between gynecologist and psychiatrist
Managing depression in women of reproductive age requires careful consideration of pregnancy plans and the potential impact of untreated depression and pharmacotherapy on fetal development. Ideally, pregnancy should occur in periods of mental stability, but being diagnosed with depression and receiving treatment are not contraindications for pregnancy. Selective serotonin reuptake inhibitors (SSRIs), particularly sertraline, are preferred due to their safety profiles, although risks such as congenital heart defects are slightly elevated. Alternatives like paroxetine carry higher risks and should be avoided when safer options are available. Electroconvulsive therapy (ECT) may be considered in cases of severe, treatment-resistant depression or when pharmacotherapy is contraindicated. Postpartum depression (PPD) is prevalent and is associated with significant risks to both mother and child if left untreated, including cognitive and emotional developmental delays in the child and increased suicide risk in the mother. Early identification and treatment are crucial, with a preference for psychotherapy in mild cases and the use of antidepressants in moderate to severe cases. During breastfeeding, the use of antidepressants such as sertraline is considered relatively safe, with careful monitoring of infant exposure. A multidisciplinary approach involving psychiatrists, gynecologists, and psychotherapists is essential to provide comprehensive care for women experiencing depression during pregnancy and the postpartum period, ensuring both maternal mental health and optimal child development.
Piśmiennictwo
1. Samochowiec J, Rybakowski J, Galecki P i wsp. Rekomendacje Polskiego Towarzystwa Psychiatrycznego dotyczące leczenia zaburzeń afektywnych u kobiet w wieku rozrodczym. Część I: Leczenie depresji. Psychiatr Pol 2019;53(2):245-62
2. Davis AR, Westhoff CL, Stanczyk FZ. Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation and bleeding. Epilepsia 2011;52(2):243-7
3. De Vries C, Gadzhanova S, Sykes MJ, et al. A systematic review and meta-analysis considering the risk for congenital heart defects of antidepressant classes and individual antidepressants. Drug Saf 2021;44(3):291-312
4. Becker M, Weinberger T, Chandy A, et al. Depression during pregnancy and postpartum. Curr Psychiatry Rep. 2016;18(3):32
5. Ward HB, Fromson JA, Cooper JJ, et al. Recommendations for the use of ECT in pregnancy: literature review and proposed clinical protocol. Arch Womens Ment Health 2018;21(6):715-22
6. Cipolla S, Catapano P, Messina M, et al. Safety of electroconvulsive therapy (ECT) in pregnancy: a systematic review of case reports and case series. Arch Womens Ment Health 2024;27(2):157-78
7. Gastaldon C, Arzenton E, Raschi E, et al. Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database. Psychol Med 2023;53(12):5645-53
8. Gwartney T, D’apolito K, Harris JB. Neonatal abstinence syndrome. In: Jnah A, McPherson C (eds). Fetal and neonatal pharmacology for the advanced practice nurse. New York: Springer Publishing Company, 2024:163-84
9. Pięta B, Bielawska-Batorowicz E, Łuczak-Wawrzyniak J i wsp. Rekomendacje do standardów organizacyjnych opieki okołoporodowej. Lublin: Polskie Towarzystwo Położnych, 2019. http://www.ptpol.pl/o-nas/rekomendacje-polskiego-towarzystwa-poloznych/44-rekomendacje-do-standardow-organizacyjnych-opieki-okoloporodowej. Dostęp 28.01.2025
10. Suchowiak S, Wszołek K, Suwalska J i wsp. Badania przesiewowe w kierunku depresji okresu okołoporodowego: przegląd narzędzi i barier w skriningu. Neuropsychiatr Neuropsychol 2020;15(1-2):60-9
11. Cantarutti A, Merlino L, Monzani E, et al. Is the risk of preterm birth and low birth weight affected by the use of antidepressant agents during pregnancy? A population-based investigation. PLoS One 2016;11(12):e0168115
12. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry 2013;74(4):e321-41
13. Niegowska KW, Kobos E. Ocena częstotliwości występowania depresji poporodowej u kobiet w pierwszym tygodniu połogu. Med Og Nauk Zdr 2019;25(4):251-7
14. Yim IS, Tanner Stapleton LR, et al. Biological and psychosocial predictors of postpartum depression: systematic review and call for integration. Annu Rev Clin Psychol 2015;11:99-137
15. Luciano M, Sampogna G, Del Vecchio V, et al. The transition from maternity blues to full-blown perinatal depression: results from a longitudinal study. Front Psychiatry 2021;12:703180
16. Massoudi P, Strömwall LA, Åhlen J, et al. Women's experiences of psychological treatment and psychosocial interventions for postpartum depression: a qualitative systematic review and meta-synthesis. BMC Womens Health 2023;23(1):604
17. Moore Simas TA, Whelan A, Byatt N. Postpartum depression – new screening recommendations and treatments. JAMA 2023;330(23):2295-6
18. FDA approves first oral treatment for postpartum depression. Food and Drug Administration, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression. Dostęp 28.01.2025
19. Batt MM, Olsavsky AK, Dardar S, et al. Course of illness and treatment updates for bipolar disorder in the perinatal period. Curr Psychiatry Rep 2022;24(2):111-20
20. Van Niel MS, Payne JL. Perinatal depression: a review. Cleve Clin J Med 2020;87(5):273-7
21. Dennis CL, Singla DR, Brown HK, et al. Postpartum depression: a clinical review of impact and current treatment solutions. Drugs 2024;84(6):645-59